Clinical trial
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
NCT06215118 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 20, 2024
- Completion date
- October 15, 2028
- Enrollment
- 100 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.